01—Abstract
Summary
Summary of the 8-K filed February 28, 2025. Cited figures are marked; the original filing is the authoritative source.
On February 28, 2025, BridgeBio Pharma, Inc. (BBIO) closed a private offering under Rule 144A of $575.0 milliona aggregate principal amount of 1.75% Convertible Senior Notes due March 1, 2031, including $75.0 million from the exercise in full of the initial purchasers' option.
The notes are senior unsecured obligations, convertible into cash, common stock, or a combination at BridgeBio's election, with an initial conversion rate of 20.0773 shares per $1,000b principal (about $49.81 per share). Net proceeds were approximately $563.0 million. BridgeBio used a portion to repay all borrowings and terminate its Financing Agreement with lenders and Blue Owl Corporation, as administrative agent, and used approximately $48.3 million to repurchase shares of its common stock from certain note purchasers at $34.35 per share, the February 25, 2025 closing price.
The filing states that the Financing Agreement, which contains various restrictive covenants, accounted for approximately $51.5 millionc of cash paid for interest in 2024, and that the refinancing is expected to reduce pro forma interest expense and provide greater operational flexibility. The company may not redeem the notes before March 6, 2028, and holders may require repurchase at 100% of principal plus accrued interest upon a fundamental change.
The notes rank equally with the company's 2.50% Convertible Senior Notes due 2027 and 2.25% Convertible Senior Notes due 2029, and are effectively junior to its secured indebtedness and structurally junior to subsidiary liabilities. BridgeBio stated that the notes were issued in reliance on Section 4(a)(2) of the Securities Act and that a maximum of 16,739,400 shares of common stock may be issued upon conversion, based on an initial maximum conversion rate of 29.1120 shares per $1,000d principal amount.
02—Key points
Key Highlights
- Issued $575.0 million of 1.75% Convertible Senior Notes due March 1, 2031, including the full $75.0 million option exercised by the initial purchasers.
- Net proceeds of approximately $563.0 million, used to repay and terminate the Financing Agreement with Blue Owl Corporation as administrative agent.
- Initial conversion price of approximately $49.81 per share (20.0773 shares per $1,000 principal), versus the $34.35 February 25, 2025 closing price referenced in the filing.
- Concurrent share repurchases of about $48.3 million of common stock at $34.35 per share from certain note purchasers, which the filing notes could affect the stock price.
- Notes cannot be redeemed before March 6, 2028, and are subject to a 130% of conversion price trading threshold for optional redemption.
- Notes are senior unsecured, pari passu with the 2.50% notes due 2027 and 2.25% notes due 2029, but effectively junior to secured debt and structurally junior to subsidiary liabilities.
- Up to 16,739,400 common shares may be issued on conversion at the initial maximum conversion rate of 29.1120 shares per $1,000 principal.
03—Questions
Frequently Asked Questions
What did BridgeBio raise, and at what terms?
BridgeBio issued $575.0 million aggregate principal amount of 1.75% Convertible Senior Notes due March 1, 2031 in a Rule 144A private offering, with interest payable semiannually on March 1 and September 1 beginning September 1, 2025. Net proceeds were approximately $563.0 million.
Why did BridgeBio enter into this financing?
The filing says the company used proceeds to repay all borrowings under its Financing Agreement and terminate it. The company stated that the Financing Agreement accounted for approximately $51.5 million of cash paid for interest in 2024 and contains various restrictive covenants, and that the refinancing will provide reduced pro forma interest expense and greater operational flexibility.
How can holders convert the notes?
Before December 2, 2030, conversion is allowed only under specified conditions, including when the stock trades at or above 130% of the conversion price for a required number of trading days in a prior quarter, when the trading price of the notes falls below 98% of the stock-based value, upon redemption calls, or upon specified corporate events. From December 2, 2030 until the second scheduled trading day before maturity, holders may convert at any time. BridgeBio may settle conversions in cash, shares, or a combination.
Will the share repurchases affect the stock?
BridgeBio used about $48.3 million of proceeds to repurchase shares from certain note purchasers at $34.35 per share, the February 25, 2025 closing price. The filing states these repurchases could increase, or reduce any decrease in, the market price of the common stock or the notes.
When can BridgeBio redeem the notes, and what happens on a fundamental change?
BridgeBio may not redeem the notes before March 6, 2028. After that, it may redeem for cash at 100% of principal plus accrued interest if the notes are freely tradable and the stock has traded at least 130% of the conversion price for 20 trading days in a 30-day period. If a fundamental change occurs, holders may require repurchase at 100% of principal plus accrued interest.
04—Continue